Granted Patent B2

US 12,221,638 · App. 17/907,538 · Granted Feb 11, 2025

Inventors: Soon Jae Park (Daejeon, KR); Kyuwan Kim (Daejeon, KR); Sang Hoon Yun (Daejeon, KR); Jeong Soo Cho (Daejeon, KR); Kibum Park (Daejeon, KR); Minsoo Byun (Daejeon, KR); Hyung-Nam Song (Daejeon, KR); Ji-Sun Kim (Daejeon, KR); Ki Seok Nam (Daejeon, KR)

Assignee: ALTEOGEN Inc.

C12N9/2474C12Y302/01035

Abstract

Claims (23)

1. A method for producing a recombinant protein that comprises at least one of hyaluronidase PH20 or a variant thereof, the method comprising:

first culturing host animal cells expressing the recombinant protein until an integral viable cell density of the host animal cells reaches 20×10 6 to 120×10 6 cells×day/mL, wherein first culturing is performed within a first temperature range from 35° C. to 38° C.; and

subsequently second culturing at least part of the host animal cells from first culturing for 2 to 18 days, which produces the recombinant protein, wherein second culturing is performed within a second temperature range from 28° C. to 34° C.,

wherein the second culturing maintains (a) a residual glucose concentration within a range from 0.001 g/L to 4.5 g/L and/or (b) pH within a range from 6.8 to 7.2 in a culture medium therefor,

wherein sialylation of N-glycan of the produced recombinant protein is 1 to 38%, and

wherein the produced recombinant protein has a hyaluronidase enzymatic activity at 10,000 units/mL or higher.

2. The method according to claim 1 , wherein galactosylation of N-glycan is 1 to 68%, and mannosylation of N-glycan is 40 to 63%.

3. The method according to claim 1 , wherein sialylation of N-glycan is 1 to 30%.

4. The method according to claim 1 , wherein the recombinant protein has a specific enzymatic activity as hyaluronidase at least 10% higher than a specific enzymatic activity of a wild human PH20.

5. The method according to claim 1 , wherein at least one of the first culturing or the second culturing are performed by one or more methods selected from the group consisting of batch culture, repeated batch culture, fed-batch culture, repeated fed-batch culture, continuous culture, and perfusion culture.

6. The method according to claim 1 , wherein at least one of the first culturing or the second culturing are performed under one or more conditions selected from the group consisting of:

(i) a condition in which an ammonia concentration is maintained at 5 mM or higher in a culture medium thereof;

(ii) a condition in which one or more substances is added to the culture medium thereof, wherein the one or more substances are selected from the group consisting of glutamine, glucosamine, uridine, glucosamine, and sodium butyrate; and

(iii) a condition in which galactose and manNAc are not added to the culture medium thereof.

7. The method according to claim 1 , wherein the recombinant protein comprises substitution of one or more amino acid residues when compared to an amino acid sequence of a wild human PH20.

8. The method according to claim 1 , further comprising separating and purifying the produced recombinant protein.

9. The method according to claim 8 , wherein separating and purifying the produced recombinant protein are performed using ionic bond and/or hydrophobic interaction characteristics thereof, rather than affinity binding.

10. The method according to claim 9 , wherein separating and purifying the recombinant protein are performed using hydrophobic interaction chromatography and ion exchange chromatography, rather than affinity chromatography.

11. The method according to claim 8 , wherein purifying further comprises removing at least part of acidic recombinant protein.

12. The method according to claim 11 , wherein removing the acidic recombinant protein uses ion exchange chromatography.

13. The method according to claim 7 , wherein the recombinant proteinfurther comprises truncation of at least one amino acid residue of N-terminus when compared to an amino acid sequence of a wild human PH20.

14. The method according to claim 7 , wherein the recombinant protein further comprises truncation of at least one amino acid residue of C-terminus when compared to an amino acid sequence of a wild human PH20.

15. The method according to claim 7 , wherein the recombinant protein further comprises truncation of at least one amino acid residue of N-terminus and at least one amino acid residue of C-terminus when compared to an amino acid sequence of a wild human PH20.

Assignments (2)

Priority Claims (1)

Continuity (1)

References Cited (273)